NR1H4 and inflammatory bowel disease: The use of Boswellia extract ininflammatory boweldisease (IBD) prompted us to explore its potential activity towardtwo known targets involved in inflammation and immunomodulation inintestinal disorders, the farnesoid X receptor (FXR) and the G protein-coupledbile acid receptor 1 (GPBAR1), and toward the leukemia inhibitoryfactor (LIF) receptor (LIFR), a tyrosine kinase receptor highly expressedin entero-hepatic tissues and gastrointestinal cancers.